You are here: Home ยป Archives for NASDAQ

Synchronoss Technologies annonce la date de la conférence téléphonique qui fera le point sur ses résultats du quatrième trimestre et son exercice 2024

BRIDGEWATER, New Jersey, 26 févr. 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (« Synchronoss » ou la « Société ») (NASDAQ : SNCR), un innovateur et leader mondial des plateformes de cloud personnel, organisera une conférence téléphonique le mardi 11 mars 2025 à 16 h 30, heure de l’Est (13 h 30, heure du Pacifique) pour faire le point sur ses résultats financiers du quatrième trimestre et sur l’ensemble de son exercice clos le 31 décembre 2024. Avant cette conférence téléphonique, les résultats financiers seront publiés dans un communiqué de presse.

La direction de Synchronoss animera la présentation, qui se poursuivra par une session de questions–réponses.

Date : mardi 11 mars 2025
Heure : 16 h 30, heure de l’Est (13 h 30, heure du Pacifique)
Numéro de téléphone : 877–451–6152 (national) ou 201–389–0879 (international)
Identifiant de la conférence : 13751475

La conférence téléphonique sera retransmise en direct ici et sur la page « Relations avec les investisseurs » du site Internet de Synchronoss.

À propos de Synchronoss
Synchronoss Technologies (Nasdaq : SNCR), un leader mondial de solutions de cloud personnalisées, permet aux prestataires de services d’établir des connexions sécurisées et pertinentes avec leurs abonnés. Notre plateforme SaaS Cloud simplifie les processus d’intégration des clients et favorise l’engagement des abonnés, avec pour résultat une amélioration des flux de revenus, une réduction des dépenses et une accélération de la mise sur le marché. Des millions d’abonnés font confiance à Synchronoss pour préserver leurs souvenirs les plus chers et les contenus numériques les plus importants. Découvrez comment nos solutions axées sur le cloud redéfinissent la manière dont vous vous connectez à votre monde numérique sur www.synchronoss.com.

Contact pour les relations avec les médias :
Domenick Cilea
Springboard
[email protected]

Contact pour les relations avec les investisseurs :
Ryan Gardella
ICR pour Synchronoss
[email protected]


GLOBENEWSWIRE (Distribution ID 9385437)

Synchronoss Technologies Announces Fourth Quarter and Full Year 2024 Earnings Call Date

BRIDGEWATER, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in Personal Cloud platforms, will hold a conference call on Tuesday, March 11, 2025 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss its financial results for the fourth quarter and full year ended December 31, 2024. Financial results will be issued in a press release prior to the call.

Synchronoss management will host the presentation, followed by a question–and–answer period.

Date: Tuesday, March 11, 2025
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial–In Number: 877–451–6152 (domestic) or 201–389–0879 (international)
Conference ID: 13751475

The conference call will be broadcast live here and via the Investor Relations section of Synchronoss’ website.

About Synchronoss
Synchronoss Technologies (Nasdaq: SNCR), a global leader in personal Cloud solutions, empowers service providers to establish secure and meaningful connections with their subscribers. Our SaaS Cloud platform simplifies onboarding processes and fosters subscriber engagement, resulting in enhanced revenue streams, reduced expenses, and faster time–to–market. Millions of subscribers trust Synchronoss to safeguard their most cherished memories and important digital content. Explore how our Cloud–focused solutions redefine the way you connect with your digital world at www.synchronoss.com.

Media Relations Contact:
Domenick Cilea
Springboard
[email protected]

Investor Relations Contact:
Ryan Gardella
ICR for Synchronoss
[email protected]


GLOBENEWSWIRE (Distribution ID 9384460)

Nanox.ARC Imaging System Receives CE Mark, Expanding Medical Imaging Offering in European Market

  • CE Mark is the first major regulatory milestone for Nanox.ARC Imaging System in the European market; follows recent general use FDA clearance in the U.S.
  • New clinical data supporting use of Nanox.ARC to be presented at European Congress of Radiology (ECR) 2025.
  • Nanox.ARC is an FDA, CE Marked, digital multi–source 3D tomosynthesis imaging system, providing advanced radiographic visualization.
  • Nanox.ARC unlocks significant value for medical practices, providers, and their patients.

PETACH TIKVA, Israel, Feb. 25, 2025 (GLOBE NEWSWIRE) — NANO–X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received CE (Conformité Européenne) mark certification to market the multi–source Nanox.ARC system, including the Nanox.CLOUD, its accompanying cloud–based infrastructure.  Nanox.ARC is a stationary X–ray system, intended to generate tomographic images of human anatomy from a single tomographic sweep performed in recumbent positions of adult patients.

The Nanox.ARC features a proprietary digital X–ray source, representing a significant advancement in X–ray technology. The system utilizes advanced tomosynthesis technology with a cold cathode to create a more comprehensive, sliced three–dimensional view of the body, enhancing visualization with multiple layers of images and reducing the super–imposition of structures often seen in 2D X–rays.

“Receiving the CE mark represents a significant milestone in our global expansion effort, building on the Nanox.ARC’s recent FDA clearance for general use,” said Erez Meltzer, Nanox Chief Executive Officer and Acting Chairman. “This certification for whole–body imaging in Europe, combined with our existing distributors and ongoing pursuit of strategic partnerships, positions us to accelerate the Nanox.ARC’s commercial introduction across the region.”

The Company believes the CE Mark may help broaden Nanox.ARC’s commercial expansion globally and specifically in Europe, where worldwide, there are a few dozen units in various stages of shipments and deployments for both commercial and clinical uses.

Nanox.ARC is intended for use in professional healthcare ‎facilities or ‎radiological ‎environments, such as ‎hospitals, clinics, imaging ‎centers and ‎other medical practices‎, and is intended to be operated by qualified personnel with the necessary knowledge and expertise to operate X–ray equipment, such as radiographers, ‎physicians, and physicists, in accordance with the relevant country–specific regulations. It is designed to allow easy and efficient integration into current clinical workflows.

Nanox.ARC’s advanced tomosynthesis system is designed to support better patient care. It bridges the gap between standard X–rays and CT scans, offering advanced clinical imaging, increasing clinicians' diagnostic confidence by allowing new clinical insights not available in conventional X–ray with only a fraction of the radiation exposure of a CT scan.

Nanox is conducting clinical trials featuring the Nanox.ARC at multiple sites and has published data demonstrating its visualization capabilities allowing clinicians utilizing the Nanox.ARC system to detect occult lesions and fractures which were not detected on conventional radiography.

Nanox will present new data further supporting the use of the Nanox.ARC at the European Congress of Radiology (ECR) 2025.

About Nanox

Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and proprietary digital X–ray source.

Nanox's vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end–to–end solution from scan to diagnosis, leveraging AI to enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment and maintaining a clinically driven approach. The Nanox ecosystem includes Nanox.ARC – a multi–source digital tomosynthesis system that is cost–effective and user–friendly; Nanox.AI LTD, a subsidiary of Nanox Imaging, an AI–based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud–based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in–depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance better health outcomes worldwide. For more information, please visit www.nanox.vision

Forward–Looking Statements

This press release may contain forward–looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward–looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X–ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward–looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward–looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward–looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third–party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox System and the proposed pay–per–scan business model; (vii) Nanox’s expectations regarding collaborations with third–parties and their potential benefits; (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces; (x) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xi) risks related to business interruptions resulting from the COVID–19 pandemic or similar public health crises, among other things; and (xii) potential litigation associated with our transactions.

For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward–Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20–F for the year ended December 31, 2023, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward–looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward–looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.

Contacts

Media Contact:
Ben Shannon
ICR Healthcare
[email protected]

Investor Contact:
Mike Cavanaugh
ICR Healthcare
[email protected]


GLOBENEWSWIRE (Distribution ID 9384213)

Society for Clinical Research Sites (SCRS) e Fortrea Fazem Parceria para Promover a Colaboração na Pesquisa Clínica

DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — A Society for Clinical Research Sites (SCRS) e a Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), tem o prazer de anunciar o patrocínio da Fortrea do grupo de trabalho SCRS Collaborate Forward.

Composto por 16 organizações líderes de Parceiros de Impacto Global, o grupo de trabalho Collaborate Forward explorará e desenvolverá as melhores práticas para reduzir os encargos administrativos em todo o ecossistema de pesquisa clínica. O grupo está empenhado em promover transparência e colaboração para enfrentar os desafios enfrentados pelos centros de pesquisa clínica. O aprimoramento dos processos internos visa tornar os sites mais sustentáveis e os ensaios mais eficientes – levando, em última análise, a uma experiência mais simplificada para os pacientes.

O patrocínio da Fortrea é um investimento significativo para a promoção da inovação em todo o setor e reflete a dedicação da empresa em colocar os sites na vanguarda do planejamento de ensaios clínicos.

“Estamos entusiasmados com a parceria com a SCRS para lançar e apoiar este grupo de trabalho”, disse Mike Clay, vice–presidente sênior de Entrega Global de Projetos da Fortrea. “Os ensaios clínicos estão se tornando cada vez mais complexos, e a indústria enfrenta uma pressão crescente para acelerar a inovação para os pacientes. Acreditamos que a colaboração com centros de pesquisa clínica é essencial para a disponibilidade de eficiências e ganhos de produtividade que irão agilizar o processo de testes clínicos. Esta iniciativa desenvolverá soluções tangíveis que patrocinadores de estudos clínicos, CROs, fornecedores, sites e grupos de defesa do paciente podem apoiar. Como CRO líder, temos orgulho de estar na vanguarda desse esforço, garantindo que os sites permaneçam centrais para impulsionar o progresso e promover maior colaboração em toda a indústria para a oferta de tratamentos que mudem mais rapidamente a vida dos pacientes.”

“A pesquisa clínica requer uma interdependência única para gerar os melhores resultados. O Collaborate Forward compartilhará sucessos de parcerias que impactam as pessoas, os processos e a tecnologia que melhoram a pesquisa clínica hoje ”, acrescentou Sean Soth, vice–presidente sênior de Estratégia e Parcerias de Negócios Globais da SCRS. “É um prazer ter a Fortrea como patrocinadora da Collaborate Forward. Essa parceria ressalta o valor da colaboração intersetorial e do esforço coletivo necessário para impulsionar um progresso significativo para a criação de um ecossistema de ensaios clínicos mais conectado e eficiente.”

O Collaborate Forward se concentrará inicialmente na inicialização do estudo, mostrando as vantagens da colaboração por meio de histórias convincentes, estudos de caso e insights baseados em dados. O grupo se reunirá regularmente para trocar ideias, avaliar as tendências do setor e desenvolver ferramentas pragmáticas que patrocinadores e CROs possam implementar em suas organizações. As atualizações sobre o progresso do grupo de trabalho serão compartilhadas ao longo de 2025 por meio de Summits e publicações da SCRS Site Solutions, destacando os principais resultados e realizações colaborativas.

A SCRS convida patrocinadores e CROs comprometidos com a sustentabilidade do site a se juntarem a esse esforço e contribuírem para moldar um cenário de pesquisa clínica mais eficaz e sinérgico. Para mais informação sobre como participar, contacte Brian Egan.

Sobre a Society for Clinical Research Sites

A Society for Clinical Research Sites (SCRS) é a principal organização de defesa dedicada a unificar a voz da comunidade global de centros de pesquisa clínica. Representando mais de 11.000 sites de pesquisa em todo o mundo, a SCRS facilita colaborações e conversas da indústria dedicadas à defesa, educação, orientação e conexão focadas no site. A SCRS é uma defensora ativa e influente de sites em iniciativas do setor para garantir que a perspectiva dos sites seja ouvida e valorizada. Saiba mais e participe em myscrs.org. Nossa voz. Nossa comunidade. Seu sucesso.

Sobre a Fortrea

A Fortrea (Nasdaq: FTRE) é fornecedora líder global de soluções para o desenvolvimento clínico para a indústria de ciências da vida. Fazemos parcerias com grandes e emergentes empresas biofarmacêuticas, de biotecnologia, de dispositivos médicos e de diagnóstico para impulsionar a inovação na saúde que acelera terapias que mudam a vida dos pacientes. A Fortrea fornece gerenciamento de testes clínicos de fase I–IV, farmacologia clínica e serviços de consultoria. As soluções da Fortrea utilizam suas três décadas de experiência abrangendo mais de 20 áreas terapêuticas, sua dedicação ao rigor científico, insights excepcionais e uma forte rede de pesquisadores. Nossa equipe talentosa e diversificada que trabalha em cerca de 100 países é dimensionada para fornecer soluções focadas e ágeis para clientes de todo o mundo. Saiba mais sobre como a Fortrea está se tornando uma força transformadora de pipeline para pacientes em Fortrea.com e siga–nos em LinkedIn e X (ex–Twitter).

Contatos da SCRS:

Marissa Hill (Mídia) – 267–865–3296, [email protected]
Brian Egan (Mídia) – 518–207–6965, [email protected]

Contatos da Fortrea:

Galen Wilson (Mídia) – 703–298–0802, [email protected]
Kate Dillon (Mídia) – 646–818–9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9362056)

La Society for Clinical Research Sites (SCRS) et Fortrea s’associent pour promouvoir la collaboration dans le domaine de la recherche clinique

DURHAM, N.C., 20 févr. 2025 (GLOBE NEWSWIRE) — La Society for Clinical Research Sites (SCRS) et Fortrea (Nasdaq : FTRE), l’une des principales organisations de recherche contractuelle (ORC) à l’international, ont le plaisir d’annoncer que Fortrea parraine désormais le groupe de travail Collaborate Forward de la SCRS.

Le groupe de travail Collaborate Forward, composé de 16 grandes organisations Global Impact Partner, a pour mission d’explorer et de développer les meilleures pratiques pour réduire la charge administrative dans l’ensemble du secteur de la recherche clinique. Le groupe s’engage à favoriser la transparence et la collaboration pour relever les défis auxquels sont confrontés les sites de recherche clinique. Il cherche à rendre les sites plus durables et les essais plus efficaces en améliorant les processus internes, ce qui permettra aux patients de bénéficier d’une expérience plus sereine.

Le parrainage de Fortrea constitue un investissement important dans la promotion de l’innovation à travers le secteur et témoigne de son engagement à donner la priorité aux sites lors de la planification des essais cliniques.

« Nous sommes ravis de travailler en partenariat avec la SCRS pour créer et accompagner ce groupe de travail », déclare Mike Clay, vice–président senior de Global Project Delivery chez Fortrea. « Les essais cliniques deviennent de plus en plus complexes et le secteur fait face à une pression croissante pour accélérer l’innovation au service des patients. Nous sommes convaincus qu’une collaboration avec les sites de recherche clinique est essentielle pour réaliser des gains d’efficacité et de productivité qui permettront de simplifier le processus d’essai clinique. Cette initiative permettra de mettre au point des solutions concrètes auxquelles les promoteurs d’études cliniques, les ORC, les fournisseurs, les sites et les groupes de défense des intérêts des patients pourront adhérer. En tant qu’ORC de premier plan, nous sommes fiers de participer à cet effort, en veillant à ce que les sites restent au cœur du progrès et en encourageant une plus grande collaboration à travers le secteur, afin de mettre plus rapidement à la disposition des patients des traitements qui changeront leur vie. »

« La recherche clinique nécessite une interdisciplinarité particulière pour générer les meilleurs résultats. Collaborate Forward partagera les réussites de partenariats qui ont un impact sur les personnes, les processus et la technologie qui améliorent la recherche clinique aujourd’hui », ajoute Sean Soth, vice–président senior de la stratégie et des partenariats commerciaux mondiaux chez la SCRS. « Nous sommes ravis de pouvoir compter sur Fortrea en tant que promoteur fondateur de Collaborate Forward. Ce partenariat souligne l’importance de la collaboration interdisciplinaire et de l’effort collectif nécessaire pour réaliser des progrès significatifs dans la création d’un système d’essais cliniques plus connecté et plus efficace. »

Collaborate Forward se concentrera d’abord sur le lancement d’études, en présentant les avantages de la collaboration par le biais de témoignages convaincants, d’études de cas et d’informations fondées sur des données. Le groupe se réunira régulièrement pour échanger des points de vue, évaluer les tendances du secteur et développer des outils pragmatiques que les promoteurs et les ORC pourront mettre en œuvre au sein de leurs organisations. Des informations sur les progrès réalisés par le groupe de travail seront communiquées tout au long de l’année 2025 lors des sommets SCRS Site Solutions ainsi que dans des publications, mettant en évidence les principaux résultats et les réussites en matière de collaboration.

La SCRS invite les promoteurs et les ORC impliqués dans la durabilité des sites à se joindre à cet effort et à contribuer à la création d’un environnement de recherche clinique plus efficace et plus dynamique. Pour plus d’informations sur les modalités de participation, veuillez contacter Brian Egan.

À propos de la Society for Clinical Research Sites

La Society for Clinical Research Sites (SCRS) est la principale organisation de défense des intérêts des sites de recherche clinique à l’échelle internationale. Représentant plus de 11 000 sites de recherche dans le monde, elle facilite les collaborations au sein du secteur et les conversations sur la défense des intérêts des sites, l’éducation, le mentorat et les relations. La SCRS est un porte–parole actif et influent pour les sites dans les initiatives du secteur, qui s’assure que le point de vue des sites est entendu et pris en compte. Pour en savoir plus et participer, consultez le site myscrs.org. Notre voix. Notre communauté. Votre succès.

À propos de Fortrea

Fortrea (Nasdaq : FTRE) est un fournisseur mondial de premier plan de solutions de développement clinique pour le secteur des sciences de la vie. Fortrea s’associe à des sociétés établies et émergentes du domaine biopharmaceutique, de la biotechnologie, des dispositifs médicaux et des diagnostics pour stimuler l’innovation en matière de santé, et accélérer la mise au point de traitements révolutionnaires pour les patients. Fortrea propose des services de gestion d’essais cliniques de phase I à IV, de pharmacologie clinique et de consulting. Nos solutions s’appuient sur 30 ans d’expérience dans 20 disciplines thérapeutiques, une passion pour la rigueur scientifique, des connaissances exceptionnelles et un solide réseau de centres de recherche. Notre équipe talentueuse et diversifiée, qui travaille dans une centaine de pays, est dimensionnée pour fournir des solutions ciblées et flexibles à nos clients, partout dans le monde. Pour en savoir plus sur la manière dont Fortrea est un moteur d’influence du pipeline au patient, rendez–vous sur Fortrea.com et suivez–nous sur LinkedIn et X (anciennement Twitter).

Contacts SCRS :

Marissa Hill (Média) – 267–865–3296, [email protected]
Brian Egan (Média) – 518–207–6965, [email protected]

Contacts Fortrea :

Galen Wilson (Média) – 703–298–0802, [email protected]
Kate Dillon (Média) – 646–818–9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9362056)

Society for Clinical Research Sites (SCRS) und Fortrea gehen eine Partnerschaft zur Förderung der Zusammenarbeit in der klinischen Forschung ein

DURHAM, North Carolina, Feb. 20, 2025 (GLOBE NEWSWIRE) — Die Society for Clinical Research Sites (SCRS) und Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (Contract Research Organization, CRO), freuen sich, die Förderung der Arbeitsgruppe „SCRS Collaborate Forward“ durch Fortrea bekanntzugeben.

Die Arbeitsgruppe „Collaborate Forward“, die aus 16 führenden Global Impact Partner–Organisationen besteht, wird bewährte Verfahren zur Reduzierung des Verwaltungsaufwands im gesamten Bereich der klinischen Forschung untersuchen und entwickeln. Die Gruppe setzt sich für Transparenz und Zusammenarbeit ein, um die Herausforderungen zu bewältigen, mit denen klinische Forschungszentren konfrontiert sind. Durch die Verbesserung interner Prozesse sollen die Standorte nachhaltiger und die Studien effizienter werden, was letztlich zu einem reibungsloseren Ablauf für die Patienten führt.

Die Förderung durch Fortrea stellt eine bedeutende Investition in die Förderung branchenweiter Innovationen dar und spiegelt das Engagement des Unternehmens wider, Prüfzentren an die Spitze der Planung klinischer Studien zu bringen.

„Wir freuen uns, mit der SCRS zusammenzuarbeiten, um diese Arbeitsgruppe ins Leben zu rufen und zu unterstützen“, so Mike Clay, Senior Vice President of Global Project Delivery bei Fortrea. „Klinische Studien werden immer komplexer und die Branche steht unter zunehmendem Druck, Innovationen für Patienten zu beschleunigen. Wir sind der Meinung, dass die Zusammenarbeit mit klinischen Forschungszentren der Schlüssel zu mehr Effizienz und Produktivitätssteigerungen ist, die den Prozess klinischer Studien optimieren werden. Diese Initiative wird konkrete Lösungen entwickeln, hinter denen sich Sponsoren klinischer Studien, CROs, Anbieter, Prüfzentren und Patientenvertretungsgruppen versammeln können. Als führendes Auftragsforschungsinstitut sind wir stolz darauf, bei diesen Bemühungen an vorderster Front zu stehen und sicherzustellen, dass die Prüfzentren weiterhin eine zentrale Rolle bei der Förderung des Fortschritts und der Förderung einer stärkeren branchenweiten Zusammenarbeit spielen, um Patienten schneller lebensverändernde Behandlungen zukommen zu lassen.“

„Klinische Forschung erfordert eine einzigartige Interdependenz, um die besten Ergebnisse zu erzielen. Collaborate Forward wird über Erfolge von Partnerschaften berichten, die sich auf die Menschen, Prozesse und Technologien auswirken und die klinische Forschung heute verbessern“, fügte Sean Soth, Senior Vice President, Strategy and Global Business Partnerships, SCRS, hinzu. „Wir freuen uns, Fortrea als Gründungssponsor von Collaborate Forward begrüßen zu dürfen. Diese Partnerschaft unterstreicht den Wert branchenübergreifender Zusammenarbeit und der gemeinsamen Anstrengungen, die erforderlich sind, um einen bedeutenden Fortschritt bei der Schaffung eines stärker vernetzten und effizienteren Ökosystems für klinische Studien zu erzielen.“

Collaborate Forward wird sich zunächst auf den Beginn von Studien konzentrieren und die Vorteile der Zusammenarbeit durch fesselnde Geschichten, Fallstudien und datengestützte Erkenntnisse aufzeigen. Die Gruppe wird regelmäßig zusammenkommen, um Erkenntnisse auszutauschen, Branchentrends zu bewerten und pragmatische Tools zu entwickeln, die Sponsoren und CROs in ihren Organisationen umsetzen können. Über den Fortschritt der Arbeitsgruppe wird im Laufe des Jahres 2025 auf den SCRS Site Solutions Summits und in Veröffentlichungen berichtet, in denen die wichtigsten Ergebnisse und Erfolge der Zusammenarbeit hervorgehoben werden.

Die SCRS lädt Sponsoren und CROs, die sich für die Nachhaltigkeit von Standorten einsetzen, ein, sich diesen Bemühungen anzuschließen und zur Gestaltung einer effektiveren und synergetischeren klinischen Forschungslandschaft beizutragen. Für weitere Informationen zur Teilnahme wenden Sie sich bitte an Brian Egan.

Über die Society for Clinical Research Sites

Die Society for Clinical Research Sites (SCRS) ist die führende Interessenvertretung, die sich dafür einsetzt, der weltweiten Gemeinschaft der klinischen Forschungszentren eine gemeinsame Stimme zu verleihen. Die SCRS vertritt mehr als 11.000 Forschungszentren weltweit und fördert die Zusammenarbeit und den Austausch in der Branche, die sich für standortbezogene Interessenvertretung, Bildung, Mentoring und Vernetzung einsetzen. Die SCRS ist ein aktiver und einflussreicher Fürsprecher für Standorte in Brancheninitiativen, um sicherzustellen, dass die Perspektive der Prüfzentren gehört und geschätzt wird. Erfahren Sie mehr und engagieren Sie sich unter myscrs.org. Unsere Stimme. Unsere Gemeinschaft. Ihr Erfolg.

Über Fortrea

Fortrea (Nasdaq: FTRE) ist ein weltweit führender Anbieter von Lösungen für die klinische Entwicklung in der Life–Science–Branche. Wir arbeiten mit aufstrebenden und großen biopharmazeutischen, biotechnologischen, medizintechnischen und diagnostischen Unternehmen zusammen, um Innovationen im Gesundheitswesen voranzutreiben, die das Angebot lebensverändernder Therapien für Patienten beschleunigen. Fortrea bietet Management von klinischen Studien der Phasen I–IV, klinische Pharmakologie und Beratungsdienste an. Die Lösungen von Fortrea basieren auf drei Jahrzehnten Erfahrung in mehr als 20 Therapiegebieten, einer Leidenschaft für wissenschaftliche Strenge, außergewöhnlichen Erkenntnissen und einem starken Netzwerk von Prüfzentren. Unser talentiertes und vielfältiges Team, das in etwa 100 Ländern tätig ist, ist darauf ausgelegt, Kunden weltweit fokussierte und flexible Lösungen zu bieten. Erfahren Sie mehr darüber, wie Fortrea von der Pipeline zum Patienten zu einer transformativen Kraft wird, unter Fortrea.com und folgen Sie uns auf LinkedIn und X (ehemals Twitter).

SCRS – Kontakte:

Marissa Hill (Medien) – 267–865–3296, [email protected]
Brian Egan (Medien) – 518–207–6965, [email protected]

Kontakt zu Fortrea:

Galen Wilson (Medien) – 703–298–0802, [email protected]
Kate Dillon (Medien) – 646–818–9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9362056)

Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research

DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea’s sponsorship of the SCRS Collaborate Forward working group.

Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficient—ultimately leading to a smoother experience for patients.

Fortrea’s sponsorship marks a significant investment in fostering industry–wide innovation and reflects the company’s dedication to placing sites at the forefront of clinical trial planning.

“We are excited to partner with SCRS to launch and support this working group,” said Mike Clay, senior vice president of Global Project Delivery at Fortrea. “Clinical trials are becoming increasingly complex, and the industry faces mounting pressure to accelerate innovation for patients. We believe that collaboration with clinical research sites is key to unlocking efficiencies and productivity gains that will streamline the clinical trial process. This initiative will develop tangible solutions that clinical study sponsors, CROs, vendors, sites and patient advocacy groups can rally behind. As a leading CRO, we are proud to be at the forefront of this effort, ensuring that sites remain central to driving progress and fostering greater industry–wide collaboration to bring life–changing treatments to patients faster.”

“Clinical research requires a unique interdependency to generate the best outcomes. Collaborate Forward will share partnership successes that impact the people, process and technology improving clinical research today,” added Sean Soth, senior vice president, Strategy and Global Business Partnerships, SCRS. “We are pleased to welcome Fortrea as the charter sponsor of Collaborate Forward. This partnership underscores the value of cross–industry collaboration and the collective effort needed to drive meaningful progress in creating a more connected and efficient clinical trial ecosystem.”

Collaborate Forward will initially focus on study startup, showcasing the advantages of collaboration through compelling stories, case studies and data–driven insights. The group will convene regularly to exchange insights, assess industry trends and develop pragmatic tools that sponsors and CROs can implement within their organizations. Updates on the working group's progress will be shared throughout 2025 via SCRS Site Solutions Summits and publications, highlighting key findings and collaborative achievements.

SCRS invites sponsors and CROs committed to site sustainability to join this effort and contribute to shaping a more effective and synergistic clinical research landscape. For more information on how to participate, please contact Brian Egan.

About The Society for Clinical Research Sites

The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites globally, SCRS facilitates industry collaborations and conversations dedicated to site–focused advocacy, education, mentorship and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your success. 

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I–IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

SCRS Contacts:

Marissa Hill (Media) – 267–865–3296, [email protected]
Brian Egan (Media) – 518–207–6965, [email protected]

Fortrea Contacts:

Galen Wilson (Media) – 703–298–0802, [email protected]
Kate Dillon (Media) – 646–818–9115, [email protected]


GLOBENEWSWIRE (Distribution ID 9361361)

EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases

JERUSALEM , Feb. 19, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO–IOF–ESCEO) Scientific Programme Committee has accepted both submitted abstracts related to EB613 for presentation at the WCO–IOF–ESCEO congress. The congress will take place at the Roma Convention Center, Rome, Italy from April 10 to April 13, 2025.

EB613 is being developed as the first once–daily oral anabolic (bone forming) PTH(1–34) tablet treatment to support earlier osteoanabolic intervention, for high–risk post–menopausal women with osteoporosis. In a Placebo–controlled Phase 2 study, 6 months of EB613 treatment demonstrated fast onset of action and robust increases in BMD at all skeletal sites. Further, EB613 induced increases in bone formation (P1NP) and suppression of bone resorption (CTX).

“EFFECTS OF EB613 TABLETS [ORAL PTH(1–34)] ON TRABECULAR AND CORTICAL BONE USING 3D–DXA: POST–HOC RESULTS FROM PHASE 2 STUDY” will be presented as an Oral Presentation Friday April 11 at 10:00 GMT in the Auditorium A.

“EB613 TABLET TREATMENT [ORAL PTH(1–34)] – DOES PK DRIVE BONE MODELING VERSUS BONE REMODELING?” will be presented as a Poster Presentation Friday April 11th – Sunday April 13th 2025.

“We thank our distinguished authors and are looking forward to sharing further mechanistic insights on EB613 with the thousands of top researchers and healthcare professionals who attend WCO–IOF–ESCEO,” said Miranda Toledano, Chief Executive Officer of Entera.

It is estimated that 50 percent of women and 20 percent of men over the age of 50 are at risk of a fragility fractures and approximately 1 in 5 adults will die within the year following a hip fracture. Post menopausal osteoporosis afflicts more women than cancer and cardiovascular disease and is a serious health concern for an estimated 200 million women globally.

EB613 is intended to provide an anabolic ‘boost’ to strengthen skeletal microarchitecture and induce rapid BMD gains, followed by consolidation with an antiresorptive agent. “Available injectable anabolic treatments, while efficacious and recommended across medical guidelines, unfortunately do not provide a viable solution for most patients with high–risk osteoporosis requiring an anabolic intervention. Our EB613 program is being developed to address the treatment chasm in current osteoporosis care and hopefully present a treatment for the majority of patients to adequately manage their bone health with a simple once daily tablet treatment,” Said Toledano.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline includes five differentiated, first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34)), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 pursuant to the FDA’s qualification of a quantitative BMD endpoint. The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP–2 peptide tablet as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this presentation are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10–K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this presentation. The information in this presentation is provided only as of the date of this presentation, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9360860)

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East
First patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates

Mont–Saint–Guibert, Belgium – February 19, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the commercial launch of its Genio system in the Middle East, marked by the first successful Genio implant performed at Saudi German Hospital, Dubai – United Arab Emirates, supported by Odin Healthcare – partnering with Nyxoah in the region.

The first patient was successfully implanted by Dr. Ahmed Yassin Bahgat, Consultant Otolaryngologist at Saudi German Hospital. Reflecting on this milestone, Dr. Bahgat stated: “We are honored to be the first hospital in the UAE, as well as the Middle East and Africa, to offer Genio to our OSA patients. Genio is an innovative, clinically proven, and smart therapy designed to effectively treat individuals with Obstructive Sleep Apnea who are unable to tolerate CPAP.”

Olivier Taelman, CEO of Nyxoah, added: “The commercial launch of Genio in the UAE marks an historic milestone as the first–ever neurostimulation therapy for Obstructive Sleep Apnea in the region. We are proud to bring this groundbreaking, patient–centric solution to the Middle East, offering new hope to patients who cannot tolerate CPAP. With strong clinical evidence and growing global adoption, we remain committed to expanding access to Genio and transforming the treatment of OSA worldwide.”

About Nyxoah
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery–free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best–in–class outcomes for reducing OSA burden.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

FORWARD–LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward–looking, reflecting Nyxoah's current expectations and beliefs regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and potential receipt of FDA approval and entrance into the U.S. market. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of Nyxoah’s Annual Report on Form 20–F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that Nyxoah files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, Nyxoah expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither Nyxoah nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

ODIN Healthcare
Ahmed Abdelhalim, Managing Director
[email protected]

For Media
In Belgium/France
Backstage Communication – Gunther De Backer
[email protected]

In International/Germany
MC Services – Anne Hennecke
nyxoah@mc–services.eu

Attachment


GLOBENEWSWIRE (Distribution ID 1001049209)

Trident et le ministère des Postes, des Télécommunications et des Technologies numériques de la République démocratique du Congo signent un accord pour la mise en œuvre du Système national d’identité numérique

SINGAPOUR, 12 févr. 2025 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd (« Trident » ou la « Société », NASDAQ : TDTH), un catalyseur majeur de la transformation numérique dans les services d’optimisation technologique et d’activation Web 3.0 basé à Singapour, a annoncé aujourd’hui la signature d’un accord de mise en œuvre avec le ministère des Postes, des Télécommunications et des Technologies numériques de la République démocratique du Congo (« RDC » ou la « République »). Cet accord marque le début du déploiement du Système national d’identité numérique.

Cet accord de collaboration préliminaire détermine le lancement opérationnel d’une plateforme globale d’identification et d’authentification numérique en RDC. Il officialise la collaboration initiale entre Trident et la République démocratique du Congo, qui évolue de la planification stratégique à l’exécution contractuelle.

Cet accord décrit des livrables spécifiques, notamment le développement et le déploiement d’un système intégré de vérification et d’authentification de l’identité numérique basé sur une infrastructure sécurisée pour la fourniture de services gouvernementaux.

En outre, ce système intégrera de solides mesures de protection des données alignées sur les normes internationales afin de garantir la sécurité et la confidentialité des informations des citoyens. Ces éléments fondamentaux visent à révolutionner les interactions entre les citoyens et le gouvernement et marquent ainsi une étape majeure vers une nation numériquement intégrée. Cette technologie profitera également aux citoyens en améliorant l’efficacité et la sécurité des services gouvernementaux, tout en garantissant le contrôle et le consentement des utilisateurs.

Déclarations de l’équipe de direction

Soon Huat Lim, fondateur, président et directeur général de Trident, a déclaré :

« La signature de cet accord représente une étape cruciale dans notre mission de fournir aux citoyens de la RDC des services d’identité numérique sécurisés et accessibles. En travaillant directement avec le ministère des Postes, des Télécommunications et des Technologies numériques, nous mettrons en œuvre des systèmes avancés de vérification et d’authentification de l’identité numérique qui serviront de pierre angulaire à la transformation numérique de la RDC. Cette phase de mise en œuvre se concentrera sur la construction d’une infrastructure robuste afin que chaque citoyen puisse accéder en toute sécurité aux services gouvernementaux grâce à une identité numérique vérifiée. »

Il a ajouté :

« Les systèmes que nous développons établiront de nouvelles normes pour la gouvernance numérique en Afrique, tout en créant un modèle reproductible pour les pays en développement. Ce partenariat est un parfait exemple de la manière dont une technologie innovante peut être exploitée pour générer des changements significatifs dans le quotidien des gens. »

Augustin Kibassa Maliba, ministre des Postes, des Télécommunications et des Technologies numériques de la RDC, a déclaré :

« Le système d’identité numérique est un pilier fondamental de la modernisation de notre pays par le biais de la transformation numérique. Avec Trident, nous serons en mesure de fournir à nos citoyens un accès sécurisé et efficace aux services gouvernementaux, tout en protégeant leurs données personnelles grâce aux progrès de la technologie blockchain. Ce partenariat démontre notre engagement à tirer parti de solutions innovantes dans l’intérêt de tous les Congolais. La mise en œuvre de cette transformation numérique se traduit par la construction d’infrastructures, mais aussi par la création de nouvelles opportunités de croissance économique et d’inclusion sociale. »

À propos de Trident

Basé à Singapour, Trident est un catalyseur pionnier de la transformation numérique dans les secteurs de l’optimisation numérique, les services technologiques et l’activation Web 3.0 à l’échelle mondiale. Cette société propose des solutions numériques commerciales et technologiques conçues pour optimiser l’expérience de ses clients auprès de leurs utilisateurs finaux en favorisant l’adoption du numérique et le libre accès.

Tridentity, son produit phare, est une solution d’identité innovante et hautement sécurisée basée sur la blockchain, conçue pour fournir des capacités d’authentification unique sécurisées aux systèmes tiers intégrés dans divers secteurs. Tridentity entend proposer des fonctionnalités de sécurité inédites afin de garantir la protection des informations sensibles et prévenir les menaces potentielles, promettant ainsi une nouvelle ère sécurisée dans le paysage numérique mondial en général, en Asie du Sud–Est, etc.

Au–delà de Tridentity, la mission de Trident est de devenir le leader mondial de l’activation Web 3.0, en connectant notamment les entreprises à une plateforme technologique fiable et sécurisée, avec des expériences client sur mesure et optimisées.

Clause de non–responsabilité

La présente annonce contient des « déclarations prospectives » (« forward–looking statements ») au sens des dispositions de la « sphère de sécurité » (« safe harbor ») du Private Securities Litigation Reform Act de 1995 des États–Unis. Ces déclarations prospectives peuvent être identifiées par l’emploi de termes tels que « sera », « s’attend », « prévoit », « entend », « futur », « a l’intention », « planifie », « croit », « estime », « susceptible de » et d’autres expressions de même sens. La Société peut également faire des déclarations prospectives écrites ou orales dans ses rapports périodiques à la Securities and Exchange Commission des États–Unis (la « SEC »), dans son rapport annuel aux actionnaires, dans des annonces et autres documents écrits, ainsi que dans des déclarations orales faites par ses dirigeants, administrateurs ou employés à des tiers. Les déclarations ne relevant pas de faits historiques, y compris les déclarations concernant les convictions, les projets et les attentes de la Société, constituent des déclarations prospectives. Les déclarations prospectives impliquent des risques et des incertitudes inhérents, y compris la possibilité qu’un accord définitif ne soit pas conclu comme le prévoit l’accord de collaboration préliminaire évoqué dans la présente annonce, et la possibilité que le système e–GOV ne se concrétise pas comme le prévoit l’accord de collaboration préliminaire ou un accord définitif éventuellement conclu. En raison d’un certain nombre de facteurs, les résultats réels pourraient différer sensiblement de ceux contenus dans des déclarations prospectives, y compris, sans toutefois s’y limiter, les éléments suivants : les stratégies, le développement commercial futur, la situation financière et les résultats d’exploitation de la Société ; la croissance attendue du marché des solutions numériques ; les évolutions politiques, économiques, sociales et juridiques dans les juridictions où la Société opère ou dans lesquelles la Société a l’intention de développer ses activités et ses opérations ; la capacité de la Société à maintenir et à améliorer sa marque. De plus amples informations concernant ces risques et d’autres risques sont incluses dans les documents déposés par la Société auprès de la SEC. Toutes les informations contenues dans la présente annonce sont fournies à la date des présentes, et la Société décline toute obligation de mettre à jour les déclarations prospectives, sauf si la loi applicable l’exige.

Contacts investisseurs et médias

Relations avec les investisseurs
Robin Yang, Associé
ICR, LLC
E–mail : [email protected] 
Téléphone : +1 (212) 321–0602

Relations avec les médias
Brad Burgess, Vice–président principal
ICR, LLC
E–mail : [email protected] 

Une photo accompagnant la présente annonce est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/1627fdde–b97d–48f2–b2b9–f50149c37570


GLOBENEWSWIRE (Distribution ID 9357435)